Wegovy 9mg Tablets: What to Expect as Your Dose Increases

If you've already taken Wegovy 1.5mg and 4mg tablets, your next prescribed dose may be Wegovy 9mg once daily.

By this stage, patients often ask whether they should be losing more weight and whether they must eventually increase to 25mg.

Where does Wegovy 9mg fit?

The standard oral Wegovy schedule is:

1.5mg → 4mg → 9mg → 25mg once daily

For a complete overview of each stage, read our Wegovy tablet dose guide.

Each stage normally lasts for at least one month.

Wegovy 9mg is therefore usually the third stage of treatment before the standard 25mg maintenance dose.

What should I expect on Wegovy 9mg?

You may notice:

• stronger appetite control
• feeling satisfied with smaller meals
• less food noise
• reduced snacking

However, not everybody notices a dramatic change when moving from 4mg to 9mg.

Semaglutide response varies between individuals, so the important thing is your overall weight and appetite trend.

How much weight should I lose on 9mg?

There isn't a specific expected weight loss for Wegovy 9mg.

The main oral semaglutide clinical study evaluated treatment using progressive dose escalation towards 25mg rather than providing separate expected results for each individual dose.

Weight loss also isn't always linear.

Some weeks you may lose more, some less and occasionally your weight may remain unchanged despite the treatment continuing to work.

What if my weight loss slows?

A plateau doesn't automatically mean Wegovy has stopped working.

Consider your:

• appetite
• portion sizes
• food choices
• physical activity
• hydration
• bowel habits
• overall weight trend

As body weight decreases, your energy requirements also change.

At Pharmulous, we don't automatically respond to a short plateau by increasing medication. We look at the whole picture.

Can side effects return on 9mg?

Yes.

Dose increases can temporarily trigger gastrointestinal symptoms such as:

• nausea
• constipation
• diarrhoea
• vomiting
• indigestion

These are particularly common during dose escalation.

Read more about Wegovy side effects and how they may be managed.

If symptoms are severe or persistent, contact the clinical team rather than simply trying to tolerate them.

How should I take Wegovy 9mg?

Take one 9mg tablet once daily after fasting for at least 8 hours.

Take it with no more than approximately 120mL of water, then wait at least 30 minutes before:

• eating
• drinking anything else
• taking other oral medicines

Correct timing is important because food can reduce how much semaglutide is absorbed.

Do I have to increase to 25mg?

25mg is the standard licensed maintenance dose, but that doesn't mean every patient must automatically rush to it.

The UK product information permits patients to remain at a previous dose level where needed.

If you're already experiencing good appetite control or approaching your weight goal, your prescriber may consider whether continuing at the current dose is appropriate.

What if 9mg is working too well?

Strong appetite suppression isn't always desirable.

If you are struggling to eat enough, losing weight excessively quickly or experiencing significant side effects, speak to your prescriber.

Eventually the objective changes from losing more weight to maintaining the weight you've lost.

This is a key part of the Pharmulous approach.

How Pharmulous can help

We don't measure treatment success by how quickly somebody reaches the highest dose.

We consider:

appetite + weight trend + tolerability + nutrition + long-term goals.

Our aim is to find weight loss or weight maintenance treatment that is effective, sustainable and clinically safe.

References

1. Novo Nordisk. Wegovy Tablets — Summary of Product Characteristics. Electronic Medicines Compendium, 2026.
2. Novo Nordisk. Wegovy Tablets — Patient Information Leaflet. Electronic Medicines Compendium, 2026.
3. MHRA. First GLP-1 tablet for weight loss approved in the UK. 11 June 2026.
4. Wharton S et al. Oral Semaglutide 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2025.